Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Belzutifan

FDA-approved product (tablet, oral), marketed as Welireg.

Registered studies
45
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Belzutifan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Clear cell renal carcinoma
  • Hemangioblastoma
  • Neoplasm
  • Pancreatic neuroendocrine tumor
  • Renal cell adenocarcinoma
  • Renal cell carcinoma
  • Von Hippel-Lindau disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
FDA pharmacologic class
Hypoxia-inducible Factor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

45registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Belzutifan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Belzutifan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

    NCT07700758 · start 2026-11-23

    Registered record
    Registry ID
    NCT07700758
    Conditions
    Malignant Neoplasm
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11-23
    Completion
    2034-01-02
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Neoplasm
    InterventionBelzutifan
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)

    NCT07793942 · start 2026-09-29

    Registered record
    Registry ID
    NCT07793942
    Conditions
    Malignant Neoplam; Advanced Solid Tumors
    Interventions
    MK-2010; Pembrolizumab; 5-Fluorouracil; Leucovorin or Levoleucovorin; Oxaliplatin; Belzutifan; Gemcitabine; Cisplatin; Carboplatin; Paclitaxel; Nab-paclitaxel; Pemetrexed; Epinephrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-29
    Completion
    2030-07-28
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Neoplam; Advanced Solid Tumors
    InterventionMK-2010; Pembrolizumab; 5-Fluorouracil; Leucovorin or Levoleucovorin +9 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma

    NCT07593040 · start 2026-06

    Registered record
    Registry ID
    NCT07593040
    Conditions
    Renal Cell Carcinoma
    Interventions
    Neoadjuvant Pembrolizumab; Belzutifan; Lenvatinb
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-06
    Completion
    2031-06
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma
    InterventionNeoadjuvant Pembrolizumab; Belzutifan; Lenvatinb
    PhasePhase 2
    Registry statusNot yet recruiting

  • TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer

    NCT07377526 · start 2026-05-26

    Registered record
    Registry ID
    NCT07377526
    Conditions
    Pancreatic Cancer
    Interventions
    TGFBR2 KO CAR27/IL-15 NK cells
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Suspended
    Start
    2026-05-26
    Completion
    2030-03-01
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionTGFBR2 KO CAR27/IL-15 NK cells
    PhasePhase 1 / Phase 2
    Registry statusSuspended

  • Belzutifan VHL RCC HK Prospective Registry

    NCT07554508 · start 2026-05

    Registered record
    Registry ID
    NCT07554508
    Conditions
    VHL - Von Hippel-Lindau Syndrome
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-05
    Completion
    2029-03-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVHL - Von Hippel-Lindau Syndrome
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • An Experimental Study of Belzutifan Impact on Catecholamine Metabolism

    NCT07680205 · start 2026-04-27

    Registered record
    Registry ID
    NCT07680205
    Conditions
    Pheochromocytoma and Paraganglioma (PPGL); Pheochromocytoma Malignant; Pheochromocytoma, Metastatic; Pheochromocytoma/Paraganglioma; Pheochromocytoma
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-04-27
    Completion
    2027-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPheochromocytoma and Paraganglioma (PPGL); Pheochromocytoma Malignant; Pheochromocytoma, Metastatic; Pheochromocytoma/Paraganglioma +1 more
    InterventionBelzutifan
    PhasePhase 2
    Registry statusRecruiting

  • A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

    NCT07489495 · start 2026-04-09

    Registered record
    Registry ID
    NCT07489495
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Belzutifan; Zanzalintinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-04-09
    Completion
    2030-11-27
    Enrolment
    758

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionBelzutifan; Zanzalintinib; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

    NCT07405164 · start 2026-03-23

    Registered record
    Registry ID
    NCT07405164
    Conditions
    Von Hippel-Lindau Disease; Malignant Neoplasms
    Interventions
    Belzutifan; Nivolumab; Lenvatinib; Cabozantinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-03-23
    Completion
    2034-01-14
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVon Hippel-Lindau Disease; Malignant Neoplasms
    InterventionBelzutifan; Nivolumab; Lenvatinib; Cabozantinib
    PhasePhase 3
    Registry statusRecruiting

  • Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

    NCT07187778 · start 2025-12-19

    Registered record
    Registry ID
    NCT07187778
    Conditions
    Clear Cell Renal Cell Carcinoma
    Interventions
    Pembrolizumab; Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-19
    Completion
    2029-07-19
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma
    InterventionPembrolizumab; Belzutifan
    PhasePhase 2
    Registry statusRecruiting

  • A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

    NCT07227402 · start 2025-11-26

    Registered record
    Registry ID
    NCT07227402
    Conditions
    Renal Cell Carcinoma
    Interventions
    Belzutifan; Zanzalintinib; Cabozantinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-11-26
    Completion
    2032-02-27
    Enrolment
    904

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma
    InterventionBelzutifan; Zanzalintinib; Cabozantinib
    PhasePhase 3
    Registry statusRecruiting

  • Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

    NCT07023432 · start 2025-11-17

    Registered record
    Registry ID
    NCT07023432
    Conditions
    Active Surveillance; Clear Cell Renal Cell Carcinoma
    Interventions
    Belzutifan; Active Surveillance
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-11-17
    Completion
    2030-04-14
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActive Surveillance; Clear Cell Renal Cell Carcinoma
    InterventionBelzutifan; Active Surveillance
    PhasePhase 2
    Registry statusRecruiting

  • Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

    NCT07179770 · start 2025-09-15

    Registered record
    Registry ID
    NCT07179770
    Conditions
    Metastatic Clear Cell Renal Cell Carcinoma
    Interventions
    Belzutifan; 89Zr-DFO-girentuximab; 89Zr-DFO-girentuximab PET
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-09-15
    Completion
    2028-10-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Clear Cell Renal Cell Carcinoma
    InterventionBelzutifan; 89Zr-DFO-girentuximab; 89Zr-DFO-girentuximab PET
    PhasePhase 1
    Registry statusRecruiting

  • A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039)

    NCT07121959 · start 2025-08-18

    Registered record
    Registry ID
    NCT07121959
    Conditions
    Healthy
    Interventions
    Metformin; Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-08-18
    Completion
    2025-09-26
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMetformin; Belzutifan
    PhasePhase 1
    Registry statusCompleted

  • Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

    NCT07049926 · start 2025-07-20

    Registered record
    Registry ID
    NCT07049926
    Conditions
    Renal Cell Carcinoma
    Interventions
    Belzutifan; Zanzalintinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-07-20
    Completion
    2031-10-26
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma
    InterventionBelzutifan; Zanzalintinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)

    NCT06903715 · start 2025-03-28

    Registered record
    Registry ID
    NCT06903715
    Conditions
    Healthy
    Interventions
    Belzutifan; Phenytoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-03-28
    Completion
    2025-05-27
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBelzutifan; Phenytoin
    PhasePhase 1
    Registry statusCompleted